ICON Public (NASDAQ:ICLR – Get Free Report) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided EPS guidance of $15.00-$15.20 for the period, compared to the consensus EPS estimate of $15.07. The company issued revenue guidance of $8.45-$8.55 billion, compared to the consensus revenue estimate of $8.64 billion.
ICON Public Stock Performance
ICLR stock traded down $18.67 on Thursday, hitting $313.10. The company’s stock had a trading volume of 1,550,372 shares, compared to its average volume of 580,845. The firm has a 50 day moving average of $322.05 and a two-hundred day moving average of $308.22. ICON Public has a 1 year low of $221.20 and a 1 year high of $347.72. The stock has a market cap of $25.83 billion, a price-to-earnings ratio of 38.14, a price-to-earnings-growth ratio of 1.48 and a beta of 1.23. The company has a current ratio of 1.21, a quick ratio of 1.21 and a debt-to-equity ratio of 0.36.
ICON Public (NASDAQ:ICLR – Get Free Report) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $3.75 EPS for the quarter, beating the consensus estimate of $3.68 by $0.07. ICON Public had a net margin of 8.30% and a return on equity of 11.70%. The firm had revenue of $2.10 billion during the quarter, compared to the consensus estimate of $2.14 billion. During the same quarter in the prior year, the firm earned $2.96 EPS. ICON Public’s revenue for the quarter was up 4.1% on a year-over-year basis. Equities analysts predict that ICON Public will post 14.54 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Check Out Our Latest Report on ICLR
ICON Public Company Profile
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Further Reading
- Five stocks we like better than ICON Public
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- Golden Cross Stocks: Pattern, Examples and Charts
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.